Real‐World Outcomes After Dupilumab Initiation for Pediatric Chronic Rhinosinusitis with Nasal Polyps
- 17 November 2026
- journal article
- Published by Wiley in Otolaryngology–Head and Neck Surgery
Abstract
Objective: To evaluate whether dupilumab initiation is associated with reduced short‐term flare burden, healthcare utilization, and surgical escalation in pediatric patients with chronic rhinosinusitis with nasal polyps (CRSwNP). Study Design: Retrospective cohort study. Setting: TriNetX United States Collaborative Network. Methods: Patients aged ≤18 years with chronic rhinosinusitis with nasal polyps were identified between January 1, 2015, and December 31, 2024. Dupilumab‐treated patients were indexed at treatment initiation and propensity score‐matched 1:1 to nondupilumab controls indexed at a systemic corticosteroid burst based on asthma, atopic dermatitis, allergic rhinitis, and prior endoscopic sinus surgery. Outcomes within 12 months were compared using risk ratios. Results: In 442 matched patients (221 per cohort), dupilumab‐treated patients had lower rates of acute sinusitis (12/221 [5.4%] vs 31/221 [14.0%]; risk ratio [RR] 0.39; 95% CI: 0.20‐0.73; P = .002), systemic corticosteroid bursts (80/221 [36.2%] vs 101/221 [45.7%]; RR 0.79; 95% CI: 0.63‐0.99; P = .042), and functional endoscopic sinus surgery (19/221 [8.6%] vs 38/221 [17.2%]; RR 0.50; 95% CI: 0.30‐0.84; P = .007). Nasal polyp diagnoses were more frequently documented in the dupilumab‐treated cohort (148/221 [67.0%] vs 95/221 [43.0%]; P < .0001), while emergency department visits (16/221 [7.2%] vs 27/221 [12.2%]; P = .078) and inpatient admissions (12/221 [5.4%] vs 16/221 [7.2%]; P = .435) were similar between cohorts. Conclusion: These findings suggest that dupilumab may be a steroid‐sparing and surgery‐sparing option in pediatric CRSwNP.This publication has 13 references indexed in Scilit:
- Biologics for Chronic Rhinosinusitis With Nasal Polyposis: Current Landscape and Future DirectionsLaryngoscope Investigative Otolaryngology, 2025
- Biologic Therapy in Pediatric Chronic Rhinosinusitis: A Systematic ReviewOtolaryngology–Head and Neck Surgery, 2024
- Chronic Rhinosinusitis With Nasal Polyposis Treated With Dupilumab: Real-World Use and OutcomesThe Journal of Allergy and Clinical Immunology: In Practice, 2023
- The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposisJournal of Allergy and Clinical Immunology, 2022
- Pediatric-onset aspirin-exacerbated respiratory disease: Clinical characteristics, prevalence, and response to dupilumabThe Journal of Allergy and Clinical Immunology: In Practice, 2022
- Chronic Rhinosinusitis with Nasal Polyps and AsthmaThe Journal of Allergy and Clinical Immunology: In Practice, 2021
- Should Oral Corticosteroids be Used in Medical Therapy for Chronic Rhinosinusitis? A Risk AnalysisThe Laryngoscope, 2020
- Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paperClinical and Translational Allergy, 2020
- Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trialsThe Lancet, 2019
- Psychometric validity of the 22‐item Sinonasal Outcome TestClinical Otolaryngology, 2009